Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVP-786 for Agitation in Alzheimer's Dementia
NCT04464564Phase 3Terminated
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Sep 2020
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 3 trial of deudextromethorphan in Alzheimer's disease (AD), sponsored by Otsuka Pharmaceutical Development & Commercialization. Started Sep 2020; status: terminated.
02
Drugs
deudextromethorphan
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04464564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04464564.